Business
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop innovative therapies that address serious neuroinflammatory and immunol
About this update from Inmune Bio Inc.
[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ESFQnG17m_59Q1hSBmvAug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO:","length":201,"tagName":"p"},{"type":"text","content":"Dear Fellow Shareholders,","length":25,"tagName":"p"},{"type":"text","content":"As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop innovative therapies that address serious neuroinflammatory and immunologic diseases with high unmet needs. 2025 was a pivotal year for our company, highlighted by compelling clinical learnings from XPro™ in our Phase 2 Alzheimer’s disease trial and significant progress advancing CORDStrom™ in Recessive Dystrophic Epidermolysis Bullosa (RDEB). Our focus on harnessing the innate immune system to address conditions with large unmet need and meaningful market potential continues to drive us forward.","length":702,"tagName":"p"},{"type":"text","content":"Starting with our most clinically advanced program, CORDStrom™, our patent-pending allogeneic umbilical cord-derived mesenchymal stromal cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), 2025 saw substantial progress. A peer-reviewed study in December highlighted the therapeutic potential of CORDStrom™, aligning with our platform’s promise.(1) We made significant strides in manufacturing, successfully completing three commercial pilot-scale runs at CGT Catapult in Stevenage, UK, in preparation for regulatory filings. I recently visited the Stevenage facility and saw firsthand the operational rigor and collaborative, problem-solving culture that is driving this program towards the patients and families living with RDEB.&nb...